計(jì)劃生育市場報(bào)告 2022.12

ReproductiveHealthSUPPLIESCOALITION4GLOBALMARKETSVISIBILITYPROJECTACKNOWL前十國家其他中低收入國家!!相較于2020年有收縮，但從2017年至2021年市場總值有相較于2020年有收縮，但從2017年至2021年市場總值有*本圖中前十的國家以2021年的數(shù)據(jù)為依據(jù)，按字母順序排列為：孟加拉、布基納法索、剛果民主共和國、埃塞俄比亞、馬拉維、莫桑比基于2021年CYP出貨量的各種避孕方法市場份額對各種方法進(jìn)行分析就2020-2021的CYP出貨量而言增長最大對各種方法進(jìn)行分析就2020-2021的CYP出貨量而言增長最大銅制IUDs銅制IUDs注射避孕藥物男用避孕套含激素IUDs女用避孕套0.6%第一次在報(bào)告中增加本方法33UNFPA在2021財(cái)年的避孕藥具采購總主要原因是受新冠疫情影響，2021UNFPA在2021財(cái)年的避孕藥具采購總主要原因是受新冠疫情影響，2021年英國外交、聯(lián)邦和發(fā)展事務(wù)部(USAID在2021財(cái)年的避孕藥具采購總在2017財(cái)年至2021財(cái)年的典型波動2022年《計(jì)劃生育市場報(bào)告》（FamilyPlanningMarketReport）介紹2021年83個(gè)中低收入國家（LowerMiddleIn場概況。此前的市場報(bào)告?zhèn)戎赜?9個(gè)FP2020重點(diǎn)國家，而今年出了更新，涵蓋了83個(gè)中低收入國家，地理范圍進(jìn)一步擴(kuò)大，這些國家現(xiàn)于2021年宣布的性與生殖健康（SexualAndReproductiveHealth購的數(shù)量，如美國國際開發(fā)署（UnitedStatesforInternationalDevelopment，U基金（UnitedNationsPopulationFund，U83個(gè)中低收入國家的衛(wèi)生部、政府關(guān)聯(lián)銷組織（SocialMarketingOrganization，采集自17家供應(yīng)商，避孕方法涵蓋女用康用品可視化系統(tǒng)（ReproductiveHealthSVisualizer，RHViz）中的發(fā)貨數(shù)2021年，公共部門市場價(jià)值相對于年，2021年的市場容量也下降了15門市場的避孕產(chǎn)品的夫妻避孕年（CoupleYe激素口服避孕藥的數(shù)量減少所導(dǎo)致的。與2017-2020年期間一樣，長效可逆避孕方法（Long-ActingMethodsofContraception-LARC），包括皮埋、銅制和激素型IUD）仍然是2021年公共部門市場已出貨類別的數(shù)據(jù)卻有所變化：從2020年至201這83個(gè)中低收入國家按照截至2020年的世界銀行收入分類進(jìn)行定義。有關(guān)FP2030將報(bào)告數(shù)據(jù)的中低收入國家的更多信息，請參見：/sites/default/files/Data-Hub/FP2030_DataReport_v5.pdf。請注意，F(xiàn)P2030報(bào)告涵蓋82個(gè)中等收入國家，比《計(jì)劃生育市場報(bào)告》涵蓋的83個(gè)國家少一個(gè)。在一定程度數(shù)據(jù)，F(xiàn)P2030目前未報(bào)告西撒哈拉（之前是69個(gè)FP2020重點(diǎn)國家之一）的相關(guān)數(shù)據(jù)。然而，在與FP2030范圍內(nèi)，因此共涵蓋83個(gè)中低收入國家。為確保國家范圍在報(bào)告所涵蓋的所有年份中保持一致，從供應(yīng)商處收集了2017-22IUD是宮內(nèi)節(jié)育器的縮寫。由于公開的激素型IUD價(jià)格于2021年首次納入U(xiǎn)3此報(bào)告長期以來使用生殖健康交流中心（ReproductiveHealthInterchange，RHI）的數(shù)據(jù)來估計(jì)男用避孕套市場的規(guī)模。由于男用避孕套市場相當(dāng)分散，RHI長期以來針對該避孕方法提供了較高的可見性。此外，RHI數(shù)據(jù)也一直用于評估《計(jì)劃生育市場報(bào)告》所涵蓋的所有避孕方法的相對可見性。然而，2020年9月，SRH社區(qū)從RHI生殖健康用品可視化系統(tǒng)(RHViz)。因此，2022年《計(jì)劃生育市場報(bào)告》現(xiàn)采用RHViz44夫妻避孕年(CYP)是指避孕方法在一年內(nèi)提供的估計(jì)避孕效果（例如，120只避孕套可為一對夫妻提供一年的避孕效果）。對于所有CYP計(jì)4本節(jié)分析了2017年至2021年公共部門市場的竺竺元收縮至2021年的2.63億美元，但仍高于83個(gè)中低收入國家的公共部門避孕市場總長，但在2020年達(dá)到峰值后，市值從少，這種產(chǎn)品成本相對較低，但CYP降600萬）以及復(fù)方和純孕激素口服避孕），CYP始終保持上升趨勢。但男用避孕套（增加200萬）就2017年至2021年間的地區(qū)至2021年，亞太地區(qū)的市場份額增加了達(dá)到28%，但在2017-2021年期間，位（附件7）。在本報(bào)告所涉及的公共部門市年的1.59億美元（附件9）。雖然逐年變化，但從2017年至2021年幽幽從2020年到2021年，市值量從2020年的600萬件下降至2021年的400萬件(從2020年至2021年，尼日6私營部門避孕用品的使用并未計(jì)入這些市場份額數(shù)據(jù)。此外，一些從孟加拉國和印度等市場的國內(nèi)供應(yīng)商處采購的產(chǎn)品可能未包含在參與供應(yīng)商的發(fā)貨數(shù)據(jù)中。因此，還應(yīng)注意的是，市場份額估計(jì)值僅基于參與供應(yīng)商的可用發(fā)貨數(shù)據(jù)。有關(guān)孟加拉國和印度市場的更多詳57如前所述，《計(jì)劃生育市場報(bào)告》基于參與供應(yīng)商的數(shù)據(jù)，介紹了孟加拉國的避孕用品采購趨勢概況。但是，除《計(jì)劃生育市場報(bào)告》中記錄的參與供應(yīng)商外，孟58由于銅制IUD的保質(zhì)期較長（約3-7年）且避孕周期也較長（放置后最長可達(dá)12年其采購周期在2020年達(dá)到6800萬美元的高位后年至2021年的避孕注射劑總體下降量降量約占40%。孟加拉國在2020年采孕注射劑，因此2021年孟加拉國避孕1）?？诜茉兴幍陌l(fā)貨量也從2020年的2.2021年的2.57億（附件2）。多個(gè)國家注：雖然采購周期波動和上述其他因素促成了2020年69激素型IUD引進(jìn)工作得到了激素型IUD獲取小組的支持，該小組是一個(gè)由政府、出資方、制造商、采購機(jī)構(gòu)（UNFPA和USAID/GHSC-PSM）、研究人員和服務(wù)提供伙球合作聯(lián)盟，旨在通過確保提供價(jià)格合理、質(zhì)量有保證的產(chǎn)品來促進(jìn)市場可持續(xù)發(fā)展，同時(shí)為準(zhǔn)備引進(jìn)該方法及擴(kuò)大其使用規(guī)模的國家（例如，政府對該方法表現(xiàn)出定引進(jìn)計(jì)劃等）提供支持，從而擴(kuò)大中低收入國家獲得激素型IUD的機(jī)會。6Exhibit1:Valueofthepublic-sectormarket(USD)TotalMarketSize(MillionsUSD) .●Condoms-Male●Condoms-FemaleInjectablesOrals-Emergency●Orals-CombinedandProgestinOnly.HormonalIUDs●ImplantsInjectablesImplants-8%**CompoundAnnualGrowthRate(CAGR):[(finalvalue/beginniNote:Thesumofindividualstackedbarsforallexhibitsmaydifferslightlyfromtotalsduetorounding.Additionally,yearoveryearandcompoundannualgrowthratenumbersarecalculatedthroughoutthereportusingactualvalues,nottheroundedvaluesinthechart.Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthesomesupplierorRHVizrevisionstohistoricaldata,basedonupdat8Exhibit2:Totalpublic-sectormarketvolumes(malecondomsexcluded*)ShipmentVolumes(Millions)●Condoms-Female●InjectablesOrals-Emergency●Orals-CombinedandProgestinOnly.HormonalIUDs●ImplantsInjectablesImplants*MalecondomsareshownseparatelybecausethesourceoftheshipmentdataisRHViz,whereasallothermethodNote:Thesumofindividualstackedbarsforallexhibitsmaydifferslightlyfromtotalsduetorounding.Additionally,yearoveryearandcompoundannualgrowthratenumbersarecalculatedthroughoutthereportusingactualvalues,nottheroundedvaluesinthechart.Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthereportversuspreviousverwellassomesupplierorRHVizrevisionstohistoricaldata,basedonu9ExhibitExhibit3:CYPsshippedtothepublic-sectormarket(Millions)00 57M●Condoms-Male●Condoms-FemaleInjectables●Orals-CombinedandProgestinOnly.HormonalIUDs●ImplantsInjectablesImplantsNote:Thesumofindividualstackedbarsforallexhibitsmaydifferslightlyfromtotalsduetorounding.Additionally,yearoveryearandcompoundannualgrowthratenumberswerecalculatedthroughoutthereportusingactualvalues,nottheroundedvaluesinthechart.Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthereportversuspreviousverswellassomesupplierorRHVizrevisionstohistoricaldata,basedonupInjectables-2monthInjectables-3monthN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AImplants-5YearIUDs(hormonal)Condoms-Male Injectables-3month Orals-CombinedOrals-ProgestinOnly Implants-3Year Injectables-2monthContraceptivePriceIndicatorhaslistedseparatepricesforthe3-yearand5-yeapriceforthisillustrativecostperCYPcalculation.ExhibitExhibit5:CYPmix(intermsofCYPsshipped)inthepublic-sectormarketshipped●Condoms-Male●Injectables●Orals-CombinedandProgestinOnly●Implants39%Note:Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthereportversuspreviousversionsduetothedifferentgeographicscopeofExhibit6:Marketsharepermethodinthepublic-sectormarket(USD)MarketValue●Condoms-Male●Condoms-FemaleInjectablesOrals-Emergency●Orals-CombinedandProgestinOnly.HormonalIUDs●Implants38%Note:Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthereportversuspreviousversionsduetothedifferentgeographicscopeofExhibit7:Marketshareofpublicsectorbyregion(USD)Market●FinalDestinationCountryNotSpeci?ed.Sub-SaharanAfrica●MiddleEast&NorthAfrica●Asia&Paci?c●LatinAmerica&CaribbeanNote:Public-sector,regionalmarketshareshowninthegraphabasmallnumberofcountriesfromboththeLatinAmerica&theseregionsarenot“Destinationcountrynotspecified”indicatesthatshipmentswerereceivedinwarehousesforlaterdistributiontoLMICs.Somedifferencesexistinthehistoricaldatafor2inthisversionofthereportversuspreviousversionsduetothedifferentsupplierscope,aswellassomesupplierorRHVizrevisionstohistoExhibit8:Toptencountriesintermsofvalue,2021Bangladesh Nigeria EthiopiaMozambiqueZambiaDemocraticRepublicofCongo Malawi Exhibit9:Valueof10largestpublic-sectorcountriescomparedtovalueofallothercountriescombined Note:Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthereportversuspreviousversionsduetothedifferentgeographicscopeofbasedonupdatedinformation.本節(jié)重點(diǎn)介紹來自UNFPA采購事務(wù)處及USAID“避孕用品與避孕套發(fā)貨概述”ContraceptiveandCondomShipments)報(bào)告中的數(shù)據(jù)10，以便了解在2017-2021期間，UNFPA在避有所下降，但仍保持在從2017-20UNFPA在避孕用品采購方面的支出總額（包括UNF的支出仍高于2017年9700萬美元的五年周期低位(所以有所下降，是因?yàn)閁NFPA當(dāng)年（OfficialDevelopmentActivities-O其中包括將其對UNFPA物資供應(yīng)項(xiàng)目的2021年的資金缺口。14方面在整體支出大幅下降，但第三方采購占UNF20%。具體而言，從2020財(cái)年至2021增加了約700萬美元（增長50%而間，第三方采購占UNFPA年度中低收對于USAID，2021財(cái)年（不包括男用和女用避孕套）15年USAID《避孕用品與避孕套發(fā)貨概內(nèi)籌資）、采購周期引起的波動以及新冠疫情。決定。正如USAID報(bào)告中所提到的，隨著US施其“自力更生之旅”(JourneytoSelf-Reli略，USAID在某些國家的駐外使團(tuán)可能10在2018年《計(jì)劃生育市場報(bào)告》發(fā)表之前，CHAI和RHSC采用RHI的數(shù)據(jù)進(jìn)行全球采購方支出分析。此后，《計(jì)劃生育市場報(bào)告》采用了來自UNF11從2020年至2021年，全球采購方支出的下降幅度大于根據(jù)供應(yīng)商發(fā)貨數(shù)據(jù)得出的83個(gè)中低收入國家公共部門市值的下降幅度，部分原因在于供應(yīng)商發(fā)貨數(shù)據(jù)包括孟加拉國和印度等國家的采購數(shù)據(jù)，這些國家利用部分國內(nèi)資金來采購避孕用品，而全球采購方支出數(shù)據(jù)中并未包含這類國內(nèi)資金。此外，供應(yīng)商發(fā)貨分析采用UNFPA避孕價(jià)計(jì)算總市值，因?yàn)檫@是定期更新的公開數(shù)據(jù)來源，但實(shí)際定價(jià)12/press/statement-uk-government-funding-cuts13/press/support-france-safeguard-health-and-lives-millions-women-and-girls?page=27,/u-s-engagement-with-the-un-14/unfpa-supplies-annual-report-202115USAID關(guān)于避孕用品發(fā)貨的數(shù)據(jù)取自“2021財(cái)年避孕用品與避孕套發(fā)貨概述報(bào)告”。2021財(cái)年的報(bào)告反映了計(jì)劃生育供資情況，但不包括H我們排除了2017財(cái)年至2021財(cái)年的女用和男用避孕套的市值，以比較不同年份的同一數(shù)據(jù)集。USAID報(bào)告可在此獲得：/sites/default17USAID的“自力更生之旅”戰(zhàn)略旨在促進(jìn)與東道國政府的合作，以加強(qiáng)地方能力、調(diào)動公共和私營部門收入并加速以企業(yè)為驅(qū)動的發(fā)展/documents/1870/journey-self-reliance-fact-sheShipmentValuestoFP2020$200M$0MExhibit11:USAIDprocurementvalue(excludingmaleandfemalecondoms)–ShipmentValuestoFP2020$40M$0M支出有所下降（這主要是由2021年），CommonwealthandDevelopmentOffice，F(xiàn)C造成的）。經(jīng)過不斷努力，UNFPA的預(yù)回彈，達(dá)到與2021年之前相當(dāng)?shù)乃秸靶跃C合預(yù)算的一部分，UNFPA表示，UNFPA2025財(cái)年的整體收入預(yù)測預(yù)計(jì)將與201年的平均避孕用品采購支出約為每年1.預(yù)測，這意味著UNFPA在未來幾年宣布削減20.5億美元的援助預(yù)算，但據(jù)了解，國際發(fā)展國務(wù)大臣AndrewMitche保障人道主義援助支出和婦女及女童方面的援助支2017-2021財(cái)年，USAID在避孕孕用品采購支出水平，USAID也將繼續(xù)品采購的資金需求很可能會繼續(xù)增長。據(jù)18/press/statement-executive-director-unfpa-integrated-budget-2022-2025-second-regular-session19/news/uk-aid-faces-third-major-cut-in-3-years-with-1-7b-to-be-cut-104513212022年3月28日，美國總統(tǒng)拜登向美國國會公布高了9%。擬向UNFPA提供的資金從2022相關(guān)項(xiàng)目”（State,ForeignOperations,andRelatedProgram，SFOP）撥款法案報(bào)告，其中提出了超出政府預(yù)算要求的資金。該法案中包括的雙邊FP/RH資金總額為8美元，為UNFPA總計(jì)撥款7000萬美元。20資金并為UNFPA提供6000萬美元的資金。在本文撰寫之時(shí)，預(yù)算對話尚在進(jìn)行中。有關(guān)信息，請?jiān)L問：/news-summary/white-house-releases-fy-2budget-request/;/news-summary/house-appropriations-committee-releases-the-fy23-state-and-foreign-operations-sfops-appropriations-bil/news-summary/senate-appropriations-committee-releases-fy23-state-and-foreign-operations-sfops-and-labor-health-and-human-services-lahhs-appropriations-bi23WeinbergerM、EvaG、GoldJ、BellowsN、ReidyM、SandersR和SkibiakJ。LEAP：生殖健康供應(yīng)需求的前景與預(yù)測。生殖健康用品聯(lián)盟，2021。報(bào)告可參見https:///#/在討論2017-2021年的市場趨勢感到驚訝，因?yàn)镕CDO在2021年宣的努力表示贊賞。SRH社區(qū)在以下方面作出了積極包括：在全球計(jì)生市場可視化與分析網(wǎng)絡(luò)（VisibilitAnalyticsNetwork，VAN）的幫助下，24確定應(yīng)缺口；UNFPASupplies在這一年為了減輕FCDO提供給UNFPA的資金水平邁進(jìn)。利益相關(guān)者還建議UNFPA汲和交付周期延長一直持續(xù)到了2021輸成本相對較高。例如，據(jù)USAID報(bào)間的長期相互影響。例如，一些國家在引入激提供針對各國避孕用品分配或消費(fèi)的看法。年到2021年，避孕用品采購市值有所下貨數(shù)據(jù)并不能用于推斷2020年至2021過去幾年來，全球新冠疫情和嚴(yán)峻的經(jīng)濟(jì)形24https://www.rhsupplies.or25/its-about-supplies/how-greater-data-visibility-helped-the-reproductive-health-community-confront-the-challenges-of-f02bdb9324ba26/press/support-france-safeguard-health-and-lives-millions-women-and-girls?page=27,/u-s-engagement-with-the-un-27/updates/international-freight-alert282021年8月，USAID對USAID監(jiān)察長辦公室的信息請求作出的回應(yīng)。網(wǎng)址：/sites/default/files/2021-11/COVID-19%20Information%2029如2016年RHSC“商品差距分析”（CommodityGapAnalysis）中所述，一般采購趨勢“也可能反映了除用戶消費(fèi)之外的一些因素，例如填充從中央倉庫到各個(gè)服務(wù)交付點(diǎn)的供應(yīng)管道及維持充足庫存水平所需的數(shù)量。采購數(shù)量可能會考慮已經(jīng)存在或訂購的供應(yīng)量、供應(yīng)鏈上的庫存持有政策以及各級供應(yīng)品的浪費(fèi)或“泄漏”。資金限制、施、未來推廣項(xiàng)目計(jì)劃以及出資方或政府本身對特定方法或產(chǎn)品的偏好也可能會影響要采購的供應(yīng)品類型和數(shù)量?！辨溄右姡ㄏ马摚?uptx_rhscpublications/Global_Contraceptive_Commodity_Gap_Analysis_20initiativethathasprovidedthereproductivehealthcommunitywithdetailedassessmentsofthepublic-Theinitiativeprovidesinsightfulandstrategicoutputssupplierstodevelopandimplementmoreeffectiveplanningproductsandservices.MOUwithCHAIorprovidedtheirinformationthroughcollaborationswiththethenGenericManufacturers17suppliersparticipatingintheproject.Thetotalpublic-sectormarketreferencedinthisreportonlyincludesdataforthepublicsector,whichisdefinedtheUnitedStatesAgencyforIntministriesofhealth,governmentaffiliatedprocurersasAlthoughsignificanteffortshavebeenmadetocollectasmuchdataaspossible,itdatainthisreportmaynotrepresenttheentiretyofcontraceptiveprocurementforthepublicsector.Thisreportincludesdatafrommost,butnotall,suppliersassociatedwiththesemark(inalphabeticalorder)corecompetenciesinhealthcareandacontraceptiveproductportfolioincludescontraceptiveinjectables.CiplaLimitedisanIndia-bahealth.Itscontraceptiveproductportfolioincludesemergencycontraceptivesandcombinedoralcontraceptives.ItalsomanufacturesmisoprostCorporateChannelsmanufactureroffemalecontraceptivedevicesbasedinprovidepermanentcontraceptionforwomen.isamanufacturerofreproductivehealthproductsbasedinChina.ItscontraceptiveproductportfolioincludesemergencyoralcontraceptivesandcombinedoralCupidLimitedisamanufacturerofbothmaleandfemaleandresearchanddevelopmandmanufacturingofitsownbrandedproducts.30TheprocurementofproductsusedforsterilizationsuchastubalringsarenotcoveredinthisdivisionofVeruHealthcarefocusingonurologyandprotectionagainstsexuallytransmittedinfectionsandInceptaandmarketsgenericdrugacrossvarioustherapeuticareas.Inceptacurrentlyexportsitsproductsto83countriesaroundtheworld.Itscontraceptiveproductportfolioincludesoral(combinedandprogestinonly)andinjectablecontraceptives.Medicines360healthpharmaceuticalcompanythatseekstocatalyzeequitableaccesstomedicinesanddevicesthproductdevelopment,policyadvocacy,andcollaborationcontraceptiveproductportfolioincludescontraceptivesterileapplicator),oralcontraceptives(Exlutonandcontraceptiveproductportfolioincludes3-monthPregnaisamanufacturerofbasedinIndia.Itscontraceptiveproductportfolioringsusedforfemalesterilization.reproductivehealthcare.Itscontraceptiveproductportfolioincludesamonthlyinjectable,athreemonthlyinjectable,acombinedoralcontraceptive,andprequalifiedstatus.Bangladesh.Itscontraceptiveproductportfolioincludescombinedoralcontraceptives,progestin-onlyoralcontraceptives,andemergencyoralcontraceptivepills.manufacturerofcontraceptiveimplantsbasedinChina.pre-qualifiedDahua’sLevoplant(foImplantII)forthreeyearsofuse.contraceptiveproductportfolioincludescombinedoralViatris(Mylan)portfolioincludesoralsolids,injectables,anddevices.BurundiDjiboutiKiribati––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––Mauritania–––––––––Philippines–––––––––––––––––––––––––––Timor-Leste––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.2:83LMICs-ContraceptivemarketvolumesBurundiDjiboutiKiribati–––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.2:83LMICs-ContraceptivemarketvolumesMauritaniaPhilippinesTimor-Leste–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.2:83LMICs-ContraceptivemarketvolumesExhibitA.2:83LMICs-Contraceptivemarketvolumes–––––––––––––––––––––––––ExhibitA.3:83LMICs-ContraceptivemarketvolumBurundiDjiboutiKiribati––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.3:83LMICs-ContraceptivemarketvolumMauritaniaPhilippinesTimor-Leste––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.3:83LMICs-ContraceptivemarketvolumExhibitA.3:83LMICs-Contraceptivemarketvolum––––––––––––––––––––––ExhibitA.4:83LMICs-Contraceptivemarketvolumesbymethod,2020BurundiDjiboutiKiribati–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.4:83LMICs-Contraceptivemarketvolumesbymethod,2020MauritaniaPhilippinesTimor-Leste––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.4:83LMICs-Contraceptivemarketvolumesbymethod,2020ExhibitA.4:83LMICs-Contraceptivemarketvolumesbymethod,2020–––––––––––––––––––––––ExhibitA.5:83LMICs-ContraceptivemarkeBurundiDjiboutiKiribati––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.5:83LMICs-ContraceptivemarkeMauritaniaPhilippinesTimor-Leste––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.5:83LMICs-ContraceptivemarkeExhibitA.5:83LMICs-Contraceptivemarke–––––––––––––––––––––––––Indevelopingthisreport’smarketanalyses,adatasourcesfrompartnerorganizationsthatprovidefamilyplanningmarketdataatthegloballevelwereavailablemetrics,coverageofcofupdates,andeaseofaccessappropriatesourcesforsustainableanalyses,thatwillbeprovidesanoverviewofthedatasourcesthisreportFP2020GlobalMarketsVisibilityProjectGlobalMarketsVisibilityProjecsuppliers,andpartnersimprovetheirunderstandingofthecurrentmarketsizeandtrendsforkeycontraceptivedatabyproductandcountryfromsuppliersforeachofthemarketreport’sgeographicscopetoincludethecollectandaggregateshipmentdatafromparticipatingreports,CHAIhascollectedshipmentdatadirectlyfromVisibilityProjecthascollectedhistoricalshipmentdatamanufacturersacrossfivefamilyplanningproductreportintheSupplierShipmentAnalysisandassociatedAppendicesarebasedonthesuppliershipmentdatacollectedthroughthisproject.U.S.AgencyforInternationalreproductivehealthactivitiessiisanannualpublicationthatsummarizescontraceptiveexcludingmaleandfemaleValuesareinclusiveofcommodityandfreightcostsandTheUnitedNationsPopulationFundsystemfortheprocurementofreproductivehealthcommoditiesandhasbeenprocuringreproductiveandtestingandarereportedbasedonReproductiveHealthSuppliescontraceptiveshipmentsvolumesviaaseriesofpublic-procurementshipmentdata(fcomparisonpointforthesupplierdatasetforahigh-levelunderstandingofsuppliershipmentdatacoverage,accordingly,thisreporthasThevalueofthepublic-sectormarketwascalculatedusingthemostcomprehensivehistoricalsupplier-reportedshipmentdataandRHVizshipmentdata.Shipmentdataisrecofollowingunits:ImplantsInjectablesThisyear’smarketreportincludeshistoricalsupplier-planningproductcateItisimportanttonotethattherewereseveralshipmentsthesevolumeswereinitiallyshippedtonon-LMICs,totalshipmentstothe83LMICsafteritwasconwithsuppliersthatthespecificnon-LMICvolumeswereassociatedwithglobalprocurerpurchases.CHAIanalyzedtheaggrreportedshipmentdatatoconfirmthatcoverageacrossthepublic-sectorproductmarketswasgreaterrelativecollectinghistoricalvolumesofallglobalprocurerfromsupplierswastoaddressdatagapsobservedinpubliclyavailableshipmentdatawhichonlycaptureasubsetofprocurerswhochosetosubmithistoricalprocurementdata.Furthermore,althoughsomecountriesreportnationalprocurements,manynationalprocurementsarenotreportedinpubliclyavailablehistoricalsupplier-reportedshipmentvolumestothe83ExhibitC.2:GlobalMarketsVisibilityProjectparticipantsandproducts33Totalshipmentoforalcontraceptivesincludescombined,progestin-only,andemergencyoralcontraceptExhibitExhibitC.3:Supplier-reportedshipmentvolumesto83LMICsbymethod,2017-2021ImplantsExhibitC.4:Supplier-reportedshipmentvolumesasapercentageofRHViz-reportedvolumesImplantsNote:Cumulativetotalscalculatedusingactual,ratherthanroundednumbers.MaleCondomMarketRHVizshipmentdataformalecondomswasusedtocaptureamorecompThesupplier-reportedvolumesforfemalecondoms,implants,injectables,IUDs,andorvolumesformalecondoms,repr34TotalyearlyvolumesarebasedontheyearthattheproductwassTotalPublic-SectorMarketinAllshipmentvolumesweredividedbythecorrespondingtheestimatedprotectionprovidedbydifferentdifferentCYPsassociatedwithseveraldiffeforthree-andfive-yearimplants)thecorrespondingexhibitshowstheconversionfactorsusedtotranslateInjectables-3month64availableat/global-health/health-areas/family-planning/couple-years-protection-cyp.ImplantsInjectablesValueoftheTotalPublic-SectorMarketThetotalvalueofcontraceptiveswascalculatedbyapplyingaverageunitpricestototalshipmentvolumes.AlthoughPriceIndicator,giventheContraceptivePrinotaccountforadditionalcostsassociatedwithprocurementsuchastesting,insurance,andshippingcosts.36UNFPA,“UNFPAContraceptivePriceIndicator—Year2021”,availableat/sites/default/files/resource-pdf/Contraceptive%20Price%20Indicator%202021.pdf,UNFPA,“UNFPAContraceptivePriceIndicator—Year2020”,availableat/sites/default/files/resource-pdf/UNFPA_Contraceptives_Price_Indicator_2020.pdf,UNFPA,“UNFPAContraceptivePriceIndicator—Year2019”,availableat/sites/default/files/resource-pdf/UNFPA_Contraceptive_Price_Indicators_2019_V2_-_EXTERNAL.pdf,UNFPA,“UNFPAContraceptivePriceIndicator–Year2018”,availableat/sites/default/fUNFPA_Contraceptive_Price_Indicators_2018_.pdf,UNFPA,“UNFPAContraceptivePriceIprice-indicator-year-2017.Toprotectcustomerconfidentiality,supplierswerenotaskedtodisclosecustomerinformationassociatedwithshipmenttwomajorglobalprocurersoffamilyplanningcommodities.Formoreinformationoneachofthesedatasources,referGoingforward,CHAIandRHSCcommoditiestoensurethedataprovidedisthemostaccurateandaccessibleforthepurposesofthisreport.ThisreporthashistoricallyincludedsupplementaryresearchandanalysisusingpubliclyavailabledatasourcesinforBangladeshandIndia.Publiclyavailabledataongovernmentpryears,soIndonesiahasbeenremovedfornowGiventhelimitationsofpubliclyavailabledatasources,thisreportcannotconfirmthatthesemarketvisibilityanalysestobeusedasinitialviewintodomesticprocurementinthesemarkets,thatmaynotbefullycoveredbythesuppliersparticipatinginthisreport.Drugs.Althoughdatafromonlyasubsetofthesemanufacturersisincludedinthesuppliershipmentdata,suppliersrepresentedintheFamilyPlanningMarketReportcomprisedalargershipmentanalysestothevolumesfromtheBangladeshMOHFWprocurementdsuppliershipmentdata.AlthoughcontraceptiveprocurementhasfluctuatedinBangladesh,consumptionhasBangladesh’ssupplychainreports42revealedthatconsumptionofcontraceptivecommoditieshasbeenfairlyconsistent4437BangladeshandIndiaaccountedforalargeproportionofthegapbetweenFP2030oncountry-specificcomparisons(per2016analysis,whnotableproportionofthegapbetweenFP2030-reportedusersofproduct-basedmethodsandusersimpliedbytheshipmentdatabutiscurrentlyexcludedfromthemarketvisibilityanalysisgivenlimitedpubliclyavailabledataonprocurementinrecentyears.38NotetheBangladeshMOHFWrecordsprocuremen41ToestimatethemarketvalueinBangladeshanPriceIndicator)throughoutthemarketvisibilityappendix.Actualpricingmaydifferinthesemarketsgiventhedifferentsuppliersandpricingparametersatplay.However,UNFPApriceshavebe